Knockdown of the CCNE1 and CDK2 genes in known CCNE1 amplified ovarian cancer cell lines has led to reduced clonogenic survival, but this has not been seen with the CDK2 inhibitor daniciclib when given as monotherapy. The gene discussed is CDK2; the disease is ovarian cancer.